Golimumab (Simponi Aria)

Provider Order Form rev. 01/02/2024

PATIENT INFORMATION

Referral Status: ☐ New Referral ☐ Updated Order ☐ Order Renewal

Patient Name: DOB: Patient Phone:

Patient Address: Patient Email:

Allergies: ☐ NKDA Weight (lbs/kg): Height (in/cm):

Sex: ☐ M / ☐ F Date of Last Infusion: Next Due Date: Preferred Location:

DIAGNOSIS *(Please provide ICD-10 code in space provided)*

Psoriatic Arthritis: Ankylosing Spondylitis: Rheumatoid Arthritis:

Other: Description:

THERAPY ADMINISTRATION & DOSING

☑ Administer golimumab (Simponi Aria) 2mg/kg IV x _____ kg = _____ mg in 100 mL 0.9% sodium chloride over a period of 30 minutes

FREQUENCY *(Choose one)*

☐ Induction: week 0, week 4, then every 8 weeks
☐ Maintenance: every 8 weeks
☐ Every _____ weeks

ADDITIONAL ORDERS

PRE-MEDICATION ORDERS

☐ Tylenol ☐ 500mg / ☐ 650mg PO
☐ Loratadine 10mg PO
☐ Pepcid 20mg ☐ PO / ☐ IVP
☐ Benadryl ☐ 25mg / ☐ 50mg ☐ PO / ☐ IVP
☐ Solumedrol ☐ 40mg / ☐ 125mg IVP
☐ Other: _____

NURSING

☑ Hold infusion and notify provider for:
- Abnormal vital signs, Fever, neurological changes, or signs/symptoms of illness/active infection
- Planned/recent surgical procedures or recent live vaccinations

☑ Provide nursing care per Nursing Procedure, including Hypersensitivity Reaction Management Protocol and post-procedure observation

PROVIDER INFORMATION

Preferred Contact Name: Preferred Contact Email:

Ordering Provider: Provider NPI:

Referring Practice Name: Phone: Fax:

Practice Address: City: State: Zip Code:

REQUIRED DOCUMENTATION CHECKLIST *(Additional documentation required for processing and insurance approval)*

Required Documentation: Patient demos, copy of front and back of primary and secondary insurance, 2 most recent OVN including treatment failures or contraindications with DMARDs, biologic agent and steroids, Colonoscopy or BSA of affected skin
Required Labs: TB, Hep B, CRP, ESR For RA: Rheumatoid factor, CCP

Provider Name *(print)* **Provider Signature** **Date**

Order valid for one year unless otherwise indicated. IV solutions/diluents may be substituted as allowed per manufacturer's instructions as necessitated by product availability.